scholarly journals Endocrine Toxicities of Antineoplastic Therapy

Cancers ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 294
Author(s):  
Giulia Puliani ◽  
Marialuisa Appetecchia
Keyword(s):  
Tyrosine Kinase ◽  
Solid Tumors ◽  
Tyrosine Kinase Inhibitors ◽  
Antineoplastic Therapy ◽  
Kinase Inhibitors ◽  
Treatment Strategies ◽  
New Treatment

In recent years, the prognosis of many solid tumors has improved markedly thanks to new treatment strategies, including tyrosine kinase inhibitors (TKIs) and immunotherapy [...]

Small Tyrosine Kinase Inhibitors as Key Molecules in the Expression of Metalloproteinases by Solid Tumors

2008 ◽  
Vol 49 (3-4) ◽  
pp. 211-214 ◽  
Author(s):  
Xanthi N. Stahtea ◽  
Olga Ch. Kousidou ◽  
Andreas E. Roussidis ◽  
George N. Tzanakakis ◽  
Nikos K. Karamanos
Keyword(s):  
Tyrosine Kinase ◽  
Solid Tumors ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors

scholarly journals More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds

2015 ◽  
Vol 10s3 ◽  
pp. BMI.S22436 ◽  
Author(s):  
Maria Vergoulidou
Keyword(s):  
Tyrosine Kinase ◽  
Small Molecules ◽  
Solid Tumors ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Progression Free Survival ◽  
Standard Of Care ◽  
Free Survival ◽  
Free Treatment

The use of tyrosine kinase inhibitors (TKIs) in the treatment of solid tumors is the expected standard of care for many types of tumors. Since the description of signal transduction pathways, followed by the development of small molecules designed to inhibit those pathways, there has been significant improvement not only in progression-free survival and overall survival but also in aiming toward chemotherapy-free treatment of solid tumors to maximize quality of life. This article reviews available TKIs and discusses toxicity, dosing, and resistance.

Sign in / Sign up

Export Citation Format

Share Document